The Office of Admissions recruits and matriculates those individuals most likely to enhance the overall health of our local, regional, national and international communities through the development of new knowledge and the provision of exemplary patient care. Each year, the School of Medicine matriculates a group of talented individuals who reflect the growing ethnic and cultural diversity of present day society, drawing on the knowledge and skills of individuals from all segments of society. Learn more about our Vision & Values.
Through innovative identification, recruitment and development programs, the School of Medicine has become recognized for the rich diversity of its student body. The Committee on Admissions has the daunting yet important job of selecting an outstanding entering freshman class each year from a bright, dedicated and diverse pool of applicants. The Committee will admit only those individuals who demonstrate the intellectual curiosity necessary for a lifetime of learning and who the Committee believes will maintain the highest standards of ethical and professional conduct.
Our students are our most prized asset and our dedicated faculty takes great joy and pride in helping each and every one of them develop into our future colleagues in the profession of medicine.
The University of Maryland, Baltimore is accredited by the Middle States Commission on Higher Education, 3624 Market St. Philadelphia, PA 19104
Maryland House of Delegates Honors University of Maryland School of Medicine Dean E. Albert Reece and University of Maryland Medical System President & CEO Robert ChrencikThe Maryland House of Delegates and House Speaker Michael E. Busch, has announced that University of Maryland School of Medicine Dean E. Albert Reece, MD, PhD, MBA and University of Maryland Medical System President and CEO Robert Chrencik, MBA, are recipients of the “Speaker’s Medallion,” the highest honor given to the public by the leader of the Maryland House of Delegates.
University of Maryland School of Medicine Researchers Identify Most Dangerous Strains of Often-Deadly BacteriaA multi-disciplinary group of researchers at the University of Maryland School of Medicine (UM SOM) have for the first time determined the genetic makeup of various strains of E. coli, which every year kills hundreds of thousands of people around the world.
University of Maryland School of Medicine Announces 'Maryland Proton Alliance' to Advance Patient-Centered Cancer Care and Precision MedicineWilliam F. Regine, MD, FACR, FACRO, Chairman of the Department of Radiation Oncology at the University of Maryland School of Medicine (UM SOM), along with UM SOM Dean E. Albert Reece, MD, PhD, MBA, today announced the establishment of the Maryland Proton Alliance (MPA), a new organizational framework for proton therapy at UM SOM that may serve as a national model for patient-centered cancer care. The Alliance will be led by Zeljko Vujaskovic, MD, PhD, Professor in the Department of Radiation Oncology and head of the department’s Division of Translational Radiation Sciences. Dr. Vujaskovic succeeds Minesh Mehta, MBChB, who served as Medical Director of the Maryland Proton Treatment Center (MPTC) during its development from 2012 to 2015.
University of Maryland School of Medicine Board Member and Benefactor Robert E. Fischell, Awarded Presidential MedalThe White House has awarded Robert E. Fischell, ScD, a member of the University of Maryland School of Medicine (UM SOM) Board of Visitors, the National Medal of Technology and Innovation, the highest honor for technological achievement bestowed by the president of the United States. Previous recipients have included such luminaries as Steven Jobs and Stephen Wozniak (Apple Computer, Inc.), Stephen D. Bechtel, Jr. (Bechtel Group, Inc.), David Packard (Hewlett-Packard Company), Clarence L. Johnson (Lockheed Corporation), Edwin H. Land (Polaroid Corporation) and Edith Flanigen (Union Carbide).
University of Maryland School of Medicine Research Leads to FDA Approval of Crucial Drug for Radiation SicknessAs a result of research performed by scientists at the University of Maryland School of Medicine (UM SOM), the U.S. Food and Drug Administration (FDA) has approved the use of a drug to treat the deleterious effects of radiation exposure following a nuclear incident. The drug, Neulasta®, is one of a very small number that have been approved for the treatment of acute radiation injury.